Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PMGC Holdings ( (ELAB) ) has issued an announcement.
On April 28, 2026, NorthStrive Biosciences filed a new U.S. patent application for its myostatin‑engineered probiotic EL-22, expanding the technology into human pharmaceutical applications targeting muscle loss. The application covers formulated drug products, specific dosing regimens and indications across a spectrum of muscle-wasting conditions, including sarcopenia, disuse atrophy, certain neurological disorders and muscle loss linked to GLP-1 weight-loss treatments.
The move broadens NorthStrive’s intellectual property around EL-22, its lead asset designed to support muscle preservation and growth, and underscores the company’s focus on muscle health therapeutics in both pharmaceutical and adjacent markets. By strengthening its IP portfolio, the PMGC subsidiary is seeking to reinforce its competitive position in muscle and metabolic health, which could have strategic implications for its value within PMGC’s diversified holdings and for stakeholders in emerging muscle-preservation therapies.
Spark’s Take on ELAB Stock
According to Spark, TipRanks’ AI Analyst, ELAB is a Neutral.
The score is held down primarily by weak financial performance (large losses, volatile revenue, and persistent cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events provide some upside through new contracts/strategic moves, but frequent equity financing adds dilution risk; valuation signals are not meaningfully supportive due to negative earnings and no dividend.
To see Spark’s full report on ELAB stock, click here.
More about PMGC Holdings
NorthStrive Biosciences Inc., a wholly owned subsidiary of PMGC Holdings Inc., is a biopharmaceutical company developing and acquiring therapeutic technologies aimed at muscle preservation, metabolic health and related conditions. PMGC Holdings is a diversified holding company that builds long-term shareholder value through strategic acquisitions, investments and disciplined capital allocation across multiple industries.
Average Trading Volume: 7,532,894
Technical Sentiment Signal: Sell
Current Market Cap: $11.08M
See more data about ELAB stock on TipRanks’ Stock Analysis page.